TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Distance visual acuity at Year 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Corneal Infiltrative Events up to Year 1
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of Microbial Keratitis up to Year 1
Endpoint domain: Adverse events/effects
Primary endpoint: Smartphone Addiction Scale Short Form
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Upper Extremity Functions-Quick Disabilities of Arm, Shoulder & Hand (Quick DASH)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Upper Extremity Functions-Reaction Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Interlimb Asymmetry - change in performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intraoperative bleeding as measured by the weight of surgical sponges used
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intraoperative bleeding as measured by the volume of blood in suction canister
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative bleeding as measured by patient-rated bleeding on Visual Analog Scale (VAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Office-measured Systolic Blood Pressure (SBP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in the EQ-5D-5L score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Percentage of Participants With Seropositivity for Neutralizing Antibodies Against Zika Virus at 28 Days Post Dose 2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Participants With Seroconversion for Neutralizing Antibodies Against Zika Virus at 28 Days Post Dose 2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Geometric Mean Titers (GMTs) for Neutralizing Antibodies Against Zika Virus at 28 Days Post Dose 2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Diagnostic accuracy of SPG for superficial endometriosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Brain beta-2 nicotinic acetylcholine receptor occupancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in walking performance (10m)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in walking performance (6m)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline ABAS-3 Score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Mean respiratory system resistance and reactance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Percent Change From Baseline in Body Weight at End of Treatment at Week 26
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percent Change From Baseline in Body Weight at End of Treatment at Week 32
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Tolerability of the Micro Expression Training Task
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nature, incidence and severity of adverse events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Change in joint swelling
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in incidence of adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of significant toxicity of tumor treating fields (TTFs)
Endpoint domain: Adverse events/effects
Primary endpoint: Feasibility of TTFs - estimated the number of patients who are unable to complete at least 30 days of TTF therapy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Early Bactericidal Activity (EBA) measured as time to positivity (TTP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of participants with urine samples negative for misuse of opioid drugs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain intensity and interference scores via NRS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional status via KOOS-JR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of Sleep via PROMIS-SD
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Change in corneal fluorescein staining total score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of AD patients with a Conner's CPT-3 d' T-score ≥ 60
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change from baseline in Conner's CPT-3 d' T-score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hepatitis B virus surface antigen (HbsAg)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Proportion of patients diagnosed with FH
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in cartilage appearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intergroup remission rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of life (SF12)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: PROMIS-10 Global Health measures
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: E-Cigarette Dependence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Combustible cigarette Dependence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under time-concentration Curve from 0 to last draw time (AUC0-t)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Participants Achieving Major or Partial Clinical Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physiological measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Thoracic event-free survival (tEFS)
Endpoint domain: Mortality/survival
Primary endpoint: Solicited local reaction frequency
Endpoint domain: Adverse events/effects
Primary endpoint: gE-Specific CD4+ T cell Response Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Frequency of various resistance mechanisms to EGFR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Biomechanical modulation of ankle stiffness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severe GVHD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Overall Response Rate (Response [R] Or Complete Response [CR]) At Day 85
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of fracture healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: percentage change in frequency of drop seizures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Changes in Delayed Discounting
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Changes in Acute Pain Perception
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Chronic Pain Severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent change in BMD at lumbar spine L1-4
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Reduction in Eczema Area and Severity Index (EASI) of at least 75%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Apposition of skin edges
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Completion rate of treatments
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Pain as assessed by Visual Analog Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 3.2 km self-paced treadmill time trial performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of fIR therapy
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of post-thrombotic syndrome (PTS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: number of Staphylococcus Aureus blood stream infections (SAB)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Pathological Complete Regression (pCR) Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Sensitivity of Acoustic Angiography; Breast Imaging
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity of Acoustic Angiography; Breast Imaging
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of Acoustic Angiography; Thyroid Imaging
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity of Acoustic Angiography; Thyroid Imaging
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: live birth rate per fresh transfer
Endpoint domain: Mortality/survival
Primary endpoint: Objective refractive changes in sphere and cylinder refraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Wall thickness (WT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Wall cross-sectional area (WCSA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: UFAA-International Physical Activity Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Evaluation of Diaphragmatic Functions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Evaluation Balance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plantar Pressure Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Referrals
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Health Services Utilization
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Participants With Adverse Events (AEs) up to 72 Hours Post-dosing
Endpoint domain: Adverse events/effects
Primary endpoint: Total Number of AEs and SAEs After Study Treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Pharmacokinetics Parameter of Area Under the Concentration-time Curve (AUC) From Time 0 to the Last Quantifiable Concentration (AUC0-last)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neurological or systemic complications
Endpoint domain: Adverse events/effects
Primary endpoint: Absolute oral bioavailability (F) (%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recovery of total radioactivity in urine and feces (Ae%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Richmond Agitation-Sedation Scale (RASS) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Screening for MAFLD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Displacement distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the curve from time 0 extrapolated to infinity for AZD0780 and total radioactivity (AUC0-inf)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum observed concentration (Cmax) for AZD0780 and total radioactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection of clonal pathogenic TP53 variants
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Mean change in ADHD-RS-5 scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of life by 36-Item Short Form Survey Instrument (SF-36)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Quality of life by Newcastle Stroke-Specific Quality of Life Measure
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Feasibility of the clean intervention
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Acceptability of the clean intervention
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mean change in function and disability
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Postoperative major complication rate
Endpoint domain: Adverse events/effects
Primary endpoint: Quality of life questionnaire (BREAST-Q)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Mechanical ventilation or death by day 28
Endpoint domain: Mortality/survival
Primary endpoint: Hypotension during anesthesia induction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in pain score using PainChek Adult
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in pain score using Abbey Pain Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Aerobic Capacity Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anti-fatigue performance
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Body composition_body fat
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Neural Synergies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Th2 Sputum Markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Maternal and Neonatal Outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Changes in Irritable Bowel Syndrome Symptom Severity Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Changes in Fecal Consistency as assessed through the Bristol Stool Form Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Changes in patients daily frequency of evacuation and diarrhea episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: MCID of the PROMIS-10
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: MCID of the TOPICS-SF
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Estimated viral reservoir size by total blood proviral DNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: CD4+ blood count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Response of ocular chronic GVHD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tolerability Assessment
Endpoint domain: Adverse events/effects
Primary endpoint: Permanent discontinuation of acalabrutinib
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Patients Who Experience Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Patients Who Experience Toxicities With Individualized Starting Dose (ISD) of Niraparib Using CTCAE v5.0
Endpoint domain: Adverse events/effects
Primary endpoint: Eye movement parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: SDMT (Symbol Digit Modalities Test) scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: McGill test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relative change in International Normalized Ratio (INR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in Sweat output
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in degree of severity of hyperhidrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to onset of claudication
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Total exercise time during a standard treadmill test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Walking ability measured using the standard Walking Impairment Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Cognitive function - The Trail Making Tests
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Cognitive function - Stroop test
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Cognitive function - verbal fluency
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Incidence of dental erosions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Digital Game Addiction Scale-7
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Revised Cyberbullying Inventory-II
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Decrease in headache days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in disabling headache days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in mean 10-point Visual Analog Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Anxiety assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Parental Satisfaction assessment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mobilization duration assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vastus Lateralis Muscle Cross-sectional Area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Number of neurons displaying changes in activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in O2 Saturation levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Filter-related primary endpoint (safety)
Endpoint domain: Adverse events/effects
Primary endpoint: Filter-related primary endpoint (performance)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Filter Retrieval-related primary endpoint
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of participants reporting prespecified local reactions within 7 days after each dose
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of participants reporting prespecified systemic events within 7 days after each dose
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of participants reporting Adverse Events (AEs) within 1 month after the last assigned vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum tolerated dose and/or Recommended Phase 2 dose of CBL0137
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of dose limiting toxicities of CBL0137
Endpoint domain: Adverse events/effects
Primary endpoint: Anti-tumor effect of CBL0137 in children with diffuse intrinsic pontine glioma (DIPG) or other H3 K27M-mutant diffuse midline gliomas
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Anti-tumor effect of CBL0137 in children with osteosarcomas
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in cross sectional area (ΔCSA) of the rectus femoris
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Scores of impulsivity measured by the Barratt scale (BIS11)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Adherence - MEMs Cap
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Adherence - Drug Weight
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Adherence - Drug Weight Change
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Level of stratum corneum (SC) hydration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Incidence of chronic post mastectomy pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pain outcomes
Primary endpoint: PASS for the NRS
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Tuberculosis probability score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Positive mycobacterial sputum test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Incidence of 68Ga-grazytracer-emergent Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Sensory block duration of the sciatic nerve block
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Regional lung stress
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Coronary plaque volume in major coronary arteries
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of high-risk coronary plaque features at month 12 after treatment initiation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes